Immunophotonics Highlights IP-001 Development at Swiss Biotech Days.

Dr. Theresa Visarius, Vice President of Business Development is sharing insights into the ongoing clinical development of IP-001 at Swiss Biotech Days, including a scientific poster session. The work highlights an innovative approach that explores how local tumor ablation may extend beyond direct tumor destruction to help initiate a systemic anti-cancer immune response.

The poster session provides an opportunity to present emerging data and engage with the scientific and biotech community on the potential of IP-001 as part of a next-generation immuno-oncology strategy.